A single institution experience with palbociclib toxicity requiring dose modifications-Reference-Cited by-同舟云学术

A single institution experience with palbociclib toxicity requiring dose modifications

Published:2017-12-07 Issue:2 Volume:168 Page:381-387
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Gong Jun,Cho May,Yu Kim Wai,Waisman James,Yuan Yuan,Mortimer Joanne^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/article/10.1007/s10549-017-4606-9/fulltext.html

Reference11 articles.

1. Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, Ettl J, Patel R, Pinter T, Schmidt M, Shparyk Y, Thummala AR, Voytko NL, Fowst C, Huang X, Kim ST, Randolph S, Slamon DJ (2015) The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol 16:25–35

2. Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S, Iwata H, Harbeck N, Zhang K, Theall KP, Jiang Y, Bartlett CH, Koehler M, Slamon DJ (2016) Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol 17:425–439

3. Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, Harbeck N, Lipatov ON, Walshe JM, Moulder S, Gauthier E, Lu DR, Randolph S, Diéras V, Slamon DJ (2016) Palbociclib and letrozole in advanced breast cancer. N Engl J Med 375(20):1925–1936

4. US Prescribing Information for Ibrance® http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207103s207000lbl.pdf . Accessed Nov 207111, 202016

5. Martin K, Bégaud B, Latry P, Miremont-Salamé G, Fourrier A, Moore N (2004) Differences between clinical trials and postmarketing use. Br J Clin Pharmacol 57(1):86–92

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Palbociclib in adults aged 70 years and older with advanced breast cancer: A phase 2 multicenter trial (Alliance A171601);Journal of Geriatric Oncology;2024-07

2. Post-marketing safety concerns with palbociclib: a disproportionality analysis of the FDA adverse event reporting system;Expert Opinion on Drug Safety;2024-04-12

3. First-line therapy with palbociclib in patients with advanced HR+/HER2− breast cancer: The real-life study PALBOSPAIN;Breast Cancer Research and Treatment;2024-04-01

4. Palbociclib in Older Patients with Advanced/Metastatic Breast Cancer: A Systematic Review;Targeted Oncology;2024-03-28

5. Drug-Drug Interactions in Patients with Breast Cancer;Journal of Biosciences and Medicines;2024